Alphatec Holdings reports Q3 2026 results

Item 2.02 Results of Operations and Financial Condition.

The following information is furnished pursuant to Item 2.02, "Results of Operations and Financial Condition," and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended², or otherwise subject to the liabilities of that section.

On October 29, 2026, Alphatec Holdings, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended September 30, 2026.¹ A copy of the press release is attached hereto as Exhibit 99.1.

The information contained in this Current Report, including the exhibit, shall not be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

99.1³

Press Release of Alphatec Holdings, Inc., dated October 29, 2026³

104³

Cover Page Interactive Data File (embedded within the Inline XBRL document)³

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Alphatec Holdings, Inc.

Date:

October 29, 2026

By:

/s/ J. Todd Koning⁴

J. Todd Koning⁴

Executive Vice President and Chief Financial Officer⁴

ATEC Reports Third Quarter Financial Results

Total revenue of $221 million, up 13% year-over-year⁵

Surgical revenue of $202 million increased 14%⁵

Case volumes grew 20% and net new surgeon users increased 25%

CARLSBAD, Calif., October 29, 2026 – Alphatec Holdings, Inc. (Nasdaq: ATEC), a spine-focused provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced financial results for the quarter ended September 30, 2026, and business highlights.

Third Quarter 2026 Financial Results

Quarter Ended

September 30, 2026

Total revenue $221 million

GAAP gross margin⁶

71.5%⁶

Non-GAAP gross margin

71.9%

GAAP operating expenses $155 million

Non-GAAP operating expenses $137 million

GAAP net income / (loss)⁶

($5) million⁶

Non-GAAP net income / (loss) $15 million

Non-GAAP adjusted EBITDA $38 million⁶

Non-GAAP adjusted EBITDA margin

17.3%

Ending cash balance $80 million⁶

Third Quarter Highlights

• Surgical revenue of $202 million increased 14%, up $25 million year-over-year

• Surgical hardware contributed $26 million to surgical growth and increased 17% year-over-year

• Adjusted EBITDA of $38 million, or 17% of revenue, expanded 400 basis points year-over-year

• Generated $6 million free cash flow with continued, positive trailing twelve-month free cash flow

• Tommy Carls joined the senior leadership team as EVP of Data Intelligence & Strategy

"Third-quarter revenue fell short of our expectations, primarily due to lower biologics attachment," said Pat Miles, Chairman and Chief Executive Officer.⁸ "We own and are addressing that shortfall, and going forward, improving biologics performance is a clear priority for us. At the same time, we continued to see very strong demand for our procedural solutions, with hardware revenue growing 17%, case volumes growing approximately 20%, and new surgeon adoption increasing 25%. These results reinforce our confidence in our procedure-focused strategy and the clinical value of our ecosystem. The disciplined execution of biologics is required to realize full procedural revenue translation, while building the foundation for the longer-term opportunity with OsteoAdapt (Theradaptive). We remain bullish on our ability to make continued progress toward increasingly profitable growth."

Financial Outlook for the Full Year 2026

For fiscal year 2026, the Company now expects total revenue of approximately $862 million⁷, including approximately $789 million of surgical revenue and approximately $73 million of EOS revenue. This outlook represents approximately 13% total revenue growth and approximately 15% surgical revenue growth for the year.

The Company now expects adjusted EBITDA of approximately $137 million⁷, reflecting continued year-over-year profitability expansion. The Company also expects approximately $10 million of free cash flow for fiscal year 2026.⁷

Financial Results Webcast

The Company will host a live webcast today at 1:30 p.m. PT / 4:30 p.m. ET. To access the live webcast, please use this link or visit the Investor Relations Events & Presentations section of ATEC's corporate website.

A replay of the webcast will remain available through the Investor Relations section of ATEC's corporate website for twelve months.

Analyst Webcast Participation

To participate in the question-and-answer session, analysts must register in advance using this link . Upon registration, access details, including a unique code, will be provided via email.

Non-GAAP Financial Information

To supplement the Company's financial statements presented in accordance with generally accepted accounting principles in the United States of America (GAAP), the Company reports certain non-GAAP financial measures listed below under "Non-GAAP Financial Measures." The Company believes that these non-GAAP financial measures provide investors with an additional tool for evaluating the Company's core performance, which management uses in its own evaluation of continuing operating performance, and provides a baseline for assessing the Company's future earnings potential. The Company's non-GAAP financial measures may not provide information that is directly comparable to that provided by other companies in the Company's industry, as other companies in the industry may calculate non-GAAP financial measures differently, particularly related to non-recurring, unusual items. Non-GAAP financial measures should be considered in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. We have not reconciled our non-GAAP financial measures for the full year 2026 because certain items that impact these figures are either uncertain or outside our control and cannot be reasonably predicted. Accordingly, a reconciliation of forward-looking, non-GAAP financial measures is not available. Included below are definitions of the non-GAAP financial measures the Company uses.

Non-GAAP Financial Measures

Free cash flow: Calculated by subtracting capital expenditures from cash flow provided by or used in operating activities. Management uses free cash flow to measure progress on its capital efficiency and cash flow initiatives.

Non-GAAP Gross Profit and Non-GAAP Gross Margin: Non-GAAP gross profit represents GAAP gross profit with adjustments to exclude the impact of certain items recorded to cost of goods sold. Such potential adjustments are described within the s